Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Hariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.0000001 from 54 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Meta analysis concluding that colchicine can reduce severity and mortality in COVID-19 patients, mortality OR 0.43 [0.32-0.58].
10 meta analyses show significant improvements with colchicine for mortality Danjuma, Elshafei, Elshiwy, Golpour, Lien, Rai, Salah, Zein, oxygen therapy Elshiwy, hospitalization Kow, and severity Yasmin.
Currently there are 54 colchicine for COVID-19 studies, showing 29% lower mortality [19‑39%], 29% lower ventilation [-15‑56%], 34% lower ICU admission [8‑52%], 19% lower hospitalization [11‑26%], and 9% more cases [-8‑29%].
Hariyanto et al., 14 Mar 2021, peer-reviewed, 5 authors.
This PaperColchicineAll
Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Timotius Ivan Hariyanto, Devina Adella Halim, Claudia Jodhinata, Theo Audi Yanto, Andree Kurniawan
Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488
Currently, there is no widely acceptable and proven effective treatment for coronavirus disease 2019 (COVID-19). Colchicine has been shown to offer a benefit in reducing the inflammation in several inflammatory diseases. This study aims to analyze the efficacy of colchicine administration and outcomes of COVID-19. We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until January 29, 2021. All articles published on COVID-19 and colchicine treatment were retrieved. The quality of the study was assessed using the Newcastle-Ottawa Scale (NOS) tool for observational studies and Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) for clinical trial studies. Statistical analysis was done using Review Manager 5.4 software. A total of eight studies with 5778 COVID-19 patients were included in this meta-analysis. This meta-analysis showed that the administration of colchicine was associated with improvement of outcomes of COVID-19 [OR 0.43 (95% CI 0.34-0.55), p < 0.00001, I 2 = 0%, fixed-effect modelling] and its subgroup which comprised of reduction from severe COVID-19 [OR 0.44 (95% CI 0.31-0.63), p < 0.00001, I 2 = 0%, fixed-effect modelling] and reduction of mortality rate from COVID-19 [OR 0.43 (95% CI 0.32-0.58), p < 0.00001, I 2 = 0%, fixed-effect modelling]. Our study suggests the routine use of colchicine for treatment modalities of COVID-19 patients. More randomized clinical trial studies are still needed to confirm the results from this study.
References
Brunetti, Diawara, Tsai, Colchicine to weather the cytokine storm in hospitalized patients with COVID-19, J Clin Med
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open
Della-Torre, Campochiaro, Cavalli, Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study, Ann Rheum Dis
Della-Torre, Della-Torre, Kusanovic, Treating COVID-19 with colchicine in community healthcare setting, Clin Immunol
Della-Torre, Ramirez, Dagna, Tresoldi, Colchicine treatment in community healthcare setting to prevent severe COVID-19, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218759
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin Exp Pharmacol Physiol
Hariyanto, Hardi, Kurniawan, Efficacy of Lopinavir/Ritonavir compared with standard care for treatment of coronavirus disease 2019 (COVID-19): a systematic review, Infect Disord Drug Targets, doi:10.2174/1871526520666201029125725
Hariyanto, Japar, Kwenandar, Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis, Am J Emerg Med
Hariyanto, Kurniawan, Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection, Transfus Apher Sci
Hariyanto, Kurniawan, Statin therapy did not improve the inhospital outcome of coronavirus disease 2019 (COVID-19) infection, Diabetes Metab Syndr
Hariyanto, Kurniawan, Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Diabetes Metab Syndr
Hariyanto, Kurniawan, Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection, J Med Virol
Hariyanto, Putri, Arisa, Situmeang, Kurniawan, Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis, Arch Gerontol Geriatr
Hariyanto, Putri, Situmeang, Kurniawan, Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection, Eur Arch Psychiatry Clin Neurosci, doi:10.1007/s00406-020-01205-z
Hariyanto, Rizki, Kurniawan, Anosmia/Hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis, Int Arch Otorhinolaryngol
Li, Liu, Mao, Predictive values of neutrophil-tolymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis, Crit Care
Lopes, Bonjorno, Giannini, randomized, double-blinded, placebo controlled clinical trial, doi:10.1101/2020.08.06.20169573
Margulis, Pladevall, Riera-Guardia, Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank, Clin Epidemiol
Piantoni, Colombo, Airò, The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al, Clin Rheumatol
Pinzon, Arango, Betancur, Clinical outcome of patients with COVID-19 pneumonia treated with corticosteroids and colchicine in Colombia, doi:10.21203/rs.3.rs-94922/v1
Reyes, Hu, Teperman, Anti-inflammatory therapy for COVID-19 infection: the case for colchicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219174
Rodriguez-Nava, Garcia, Yanez-Bello, Chung, Garcia et al., Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study, Crit Care
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection, Can J Infect Dis Med Microbiol
Scarsi, Piantoni, Colombo, Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep
Sterne, Savović, Page, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ
Tardif, Bouabdallaoui, Allier, Efficacy of colchicine in non-hospitalized patients with COVID-19, doi:10.1101/2021.01.26.21250494
Vitiello, Ferrara, Pelliccia, Granata, Porta, Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia, Ital J Med
{ 'DOI': '10.1111/1440-1681.13488', 'ISSN': ['0305-1870', '1440-1681'], 'URL': 'http://dx.doi.org/10.1111/1440-1681.13488', 'abstract': '<jats:title>Abstract</jats:title><jats:p>Currently, there is no widely acceptable and proven ' 'effective treatment for coronavirus disease 2019 (COVID‐19). Colchicine has been shown to ' 'offer a benefit in reducing the inflammation in several inflammatory diseases. This study ' 'aims to analyze the efficacy of colchicine administration and outcomes of COVID‐19. We ' 'systematically searched the PubMed and Europe PMC database using specific keywords related to ' 'our aims until January 29, 2021. All articles published on COVID‐19 and colchicine treatment ' 'were retrieved. The quality of the study was assessed using the Newcastle–Ottawa Scale (NOS) ' 'tool for observational studies and Revised Cochrane risk‐of‐bias tool for randomized trials ' '(RoB 2) for clinical trial studies. Statistical analysis was done using Review Manager 5.4 ' 'software. A total of eight studies with 5778 COVID‐19 patients were included in this ' 'meta‐analysis. This meta‐analysis showed that the administration of colchicine was associated ' 'with improvement of outcomes of COVID‐19 [OR 0.43 (95% CI 0.34–0.55), ' '<jats:italic>p</jats:italic>\xa0&lt;\xa00.00001, ' '<jats:italic>I</jats:italic><jats:sup>2</jats:sup>\xa0=\xa00%, fixed‐effect modelling] and ' 'its subgroup which comprised of reduction from severe COVID‐19 [OR 0.44 (95% CI 0.31–0.63), ' '<jats:italic>p</jats:italic>\xa0&lt;\xa00.00001, ' '<jats:italic>I</jats:italic><jats:sup>2</jats:sup>\xa0=\xa00%, fixed‐effect modelling] and ' 'reduction of mortality rate from COVID‐19 [OR 0.43 (95% CI 0.32–0.58), ' '<jats:italic>p</jats:italic>\xa0&lt;\xa00.00001, ' '<jats:italic>I</jats:italic><jats:sup>2</jats:sup>\xa0=\xa00%, fixed‐effect modelling]. Our ' 'study suggests the routine use of colchicine for treatment modalities of COVID‐19 patients. ' 'More randomized clinical trial studies are still needed to confirm the results from this ' 'study.</jats:p>', 'alternative-id': ['10.1111/1440-1681.13488'], 'assertion': [ { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2021-01-13'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 1, 'value': '2021-02-13'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 2, 'value': '2021-03-14'}], 'author': [ { 'affiliation': [ { 'name': 'Faculty of Medicine Pelita Harapan University Karawaci, ' 'Tangerang Indonesia'}], 'family': 'Hariyanto', 'given': 'Timotius Ivan', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Faculty of Medicine Pelita Harapan University Karawaci, ' 'Tangerang Indonesia'}], 'family': 'Halim', 'given': 'Devina Adella', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Faculty of Medicine Pelita Harapan University Karawaci, ' 'Tangerang Indonesia'}], 'family': 'Jodhinata', 'given': 'Claudia', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Internal Medicine Faculty of Medicine Pelita ' 'Harapan University Karawaci, Tangerang Indonesia'}], 'family': 'Yanto', 'given': 'Theo Audi', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-5219-9029', 'affiliation': [ { 'name': 'Department of Internal Medicine Faculty of Medicine Pelita ' 'Harapan University Karawaci, Tangerang Indonesia'}], 'authenticated-orcid': False, 'family': 'Kurniawan', 'given': 'Andree', 'sequence': 'additional'}], 'container-title': 'Clinical and Experimental Pharmacology and Physiology', 'container-title-short': 'Clin Exp Pharma Physio', 'content-domain': {'crossmark-restriction': True, 'domain': ['onlinelibrary.wiley.com']}, 'created': {'date-parts': [[2021, 3, 15]], 'date-time': '2021-03-15T03:14:32Z', 'timestamp': 1615778072000}, 'deposited': { 'date-parts': [[2023, 9, 2]], 'date-time': '2023-09-02T01:02:30Z', 'timestamp': 1693616550000}, 'indexed': {'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T18:31:46Z', 'timestamp': 1715625106161}, 'is-referenced-by-count': 51, 'issue': '6', 'issued': {'date-parts': [[2021, 3, 14]]}, 'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2021, 6]]}}, 'language': 'en', 'license': [ { 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 3, 14]], 'date-time': '2021-03-14T00:00:00Z', 'timestamp': 1615680000000}}], 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/1440-1681.13488', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1440-1681.13488', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/1440-1681.13488', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '311', 'original-title': [], 'page': '823-830', 'prefix': '10.1111', 'published': {'date-parts': [[2021, 3, 14]]}, 'published-online': {'date-parts': [[2021, 3, 14]]}, 'published-print': {'date-parts': [[2021, 6]]}, 'publisher': 'Wiley', 'reference': [ { 'key': 'e_1_2_9_2_1', 'unstructured': 'World Health Organization.Coronavirus disease (COVID‐19): situation ' 'report.https://www.who.int/publications/m/item/weekly‐epidemiological‐update'}, {'DOI': '10.1055/s-0040-1719120', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_3_1'}, {'DOI': '10.1002/jmv.26698', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_4_1'}, {'DOI': '10.1016/j.ajem.2020.12.076', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_5_1'}, {'DOI': '10.1016/j.dsx.2020.07.044', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_6_1'}, { 'DOI': '10.1016/j.transci.2020.102926', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_7_1'}, { 'DOI': '10.1016/j.archger.2020.104299', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_8_1'}, { 'article-title': 'Dementia is a predictor for mortality outcome from coronavirus disease ' '2019 (COVID‐19) infection', 'author': 'Hariyanto TI', 'first-page': '1', 'journal-title': 'Eur Arch Psychiatry Clin Neurosci', 'key': 'e_1_2_9_9_1', 'year': '2020'}, {'DOI': '10.1016/j.dsx.2020.08.023', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_10_1'}, { 'DOI': '10.2174/1871526520666201029125725', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_11_1'}, { 'article-title': 'Cytokine storm and colchicine potential role in fighting SARS‐CoV‐2 ' 'pneumonia', 'author': 'Vitiello A', 'first-page': '88', 'issue': '2', 'journal-title': 'Ital J Med', 'key': 'e_1_2_9_12_1', 'volume': '14', 'year': '2020'}, {'DOI': '10.2147/CLEP.S66677', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_13_1'}, {'DOI': '10.1136/bmj.l4898', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_14_1'}, {'DOI': '10.3390/jcm9092961', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_15_1'}, { 'DOI': '10.1001/jamanetworkopen.2020.13136', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_16_1'}, { 'article-title': 'Beneficial effects of colchicine for moderate to severe COVID‐19: an ' 'interim analysis of a randomized, double‐blinded, placebo controlled ' 'clinical trial', 'author': 'Lopes MIF', 'journal-title': 'medRxiv', 'key': 'e_1_2_9_17_1', 'year': '2020'}, { 'article-title': 'Clinical outcome of patients with COVID‐19 pneumonia treated with ' 'corticosteroids and colchicine in Colombia', 'author': 'Pinzon MA', 'journal-title': 'Research Square', 'key': 'e_1_2_9_18_1', 'year': '2020'}, {'DOI': '10.1186/s13054-020-03154-4', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_19_1'}, {'DOI': '10.1155/2020/8865954', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_20_1'}, { 'DOI': '10.1136/annrheumdis-2020-217712', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_21_1'}, { 'article-title': 'Efficacy of colchicine in non‐hospitalized patients with COVID‐19', 'author': 'Tardif JC', 'journal-title': 'medRxiv', 'key': 'e_1_2_9_22_1', 'year': '2020'}, {'DOI': '10.1016/j.clim.2020.108490', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_23_1'}, { 'DOI': '10.1136/annrheumdis-2020-218759', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_24_1'}, {'DOI': '10.1007/s40495-020-00225-6', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_25_1'}, {'DOI': '10.1186/s13054-020-03374-8', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_26_1'}, {'DOI': '10.1007/s10067-020-05232-y', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_27_1'}, { 'DOI': '10.1136/annrheumdis-2020-219174', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_28_1'}, { 'DOI': '10.1136/annrheumdis-2020-218122', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_29_1'}], 'reference-count': 28, 'references-count': 28, 'relation': {}, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1111/1440-1681.13488'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic ' 'review and meta‐analysis', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'volume': '48'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit